-
Disease Description:
Methicillin-Resistant Staphylococcus Aureus (MRSA) is a bacterium responsible for several difficult-to-treat infections in humans. It may also be referred to as multidrug-resistant Staphylococcus aureus or oxacillin-resistant Staphylococcus aureus (ORSA). MRSA is by definition any strain of Staphylococcus aureus bacteria that is resistant to a large group of antibiotics called the beta-lactams, which include the penicillins and the cephalosporins.
MRSA has adapted to survive treatment with beta-lactam antibiotics, including methicillin, dicloxacillin, nafcillin, and oxacillin. MRSA is especially troublesome in hospital-associated (nosocomial) infections. In hospitals, patients with open wounds, invasive devices, and weakened immune systems are at greater risk for infection than the general public. Hospital staff who do not follow proper sanitary procedures may transfer bacteria from patient to patient. Visitors to patients with MRSA infections or MRSA colonization are advised to follow hospital isolation protocol by using gloves, gowns, and masks when indicated. Visitors, including health care providers, who do not follow such protocols are capable of spreading the bacteria to areas such as cafeterias, bathrooms, elevators, or various other surfaces.
Current Treatment:
Currently MRSA is treated with a variety of antibiotic treatments. However, as more and more anitibiotic resistant strains emerge, medical professional struggle to find treatments to circumvent the resistance.
Evidence for Cannabinoids:
Cannabinoids have long been known to have antibacterial properties, and in one study at the Università del Piemonte Orientale, all 5 major cannabinoids (cannabinol, cannabichromene, cannabigerol, Delta (9)-tetrahydrocannabinol, and cannabinol) showed "potent activity against a variety of Methicillin-Resistant Staphylococcus Aureus (MRSA) strains of current clinical relevance."
Proposed Mechanism for Cannabinoid Therapeutics
While the evidence shows a highly potent antibiotic effect, scientists are unable to explain the mechanism of activity. - Rahman M. et al., Antibacterial Cannabinoids from Cannabis Sativa: A Structure - Activity Study. J. Nat. Prod. 2008, 71, 1427–1430
-
Category
Critical Ailments -
Created
Thursday, 16 March 2017 -
Group admin
CBIS
American States University
Click the Below Image Visit our CSi-Crypto Pre-Launch Specials !!!
*** Get Ready, the Time is Now ...
1-Million Strong Killing Cancers!
Click the Below Image to Review our Cancer Drug Comparables
*** Warning this document contains graphic images.
CSi-VIP Awards & NASDAQ Updates
Please Click the Below Image:
1st HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.
2nd HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.
*** PLUS
(3) other Cannabis Science
REAL WORLD Successes:
Stage 4 Breast Cancer
Skin Cancer
Karposis Sarcoma
The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
Photos
Observational Studies
CSi-VIP & CBIS-Shareholder Legacy
June 1, 2025, Pre-Launch Success
Click the above Image link to setup your Account and begin your Crypto Journey with us. All Crypto Coin Buyers receive a Limited Time offer!
Click the ABOVE Image to Review our 1-Million Strong FC, Media Kit
*** Warning this document contains exciting images.
Pease Click the Calendar image to book your time to speak with Mr. Dabney about "Your Final CSi-VIP Shareholder Legacy".
Click the above Image to become one of the First 1-Million Strong Killing Cancers, Fight Club Members to help 'Make that Change' Join in Now! *** Warning this Membership contains Exciting Results.
PS ... ALL of our CSi-VIP's and those who Donated through the ASU/CSi-EDP GO-Fund-Me Promotion you do not need to purchase anything, you are ALREADY included in the "First" 1-Million Membership Club, CONGRATULATIONS !!!
Cannabis Science CEO, Presents …
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 2024, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.
2025 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2025
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,839,095,296
Fully Diluted:
4,510,547,648
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
Activity Stream
We are LIVE !!! June 1, 2025 Pre-Launch Specials! 1-Million Strong Killing Cancers Foundation, CSi Labs (CSL) MEME Coins!
...
Show more
what happened with gift shares?
Soon, we Start Running towards our Goals!
But no matter what, we keep moving Forward.
Thanks Guys! May God Bless us ALL... Show more
Little bit of Action thus far, Momentum on our side.
Prices do fluctuate, you ALREADY Know.
Congrats to those who got... Show more